Neuroscience News4d
New Cell Targets Offer Hope for Treating Glioblastoma
Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this ...
ascopubs.org23d
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...
precisionmedicineonline14d
Pfizer's Ibrance Shows Benefit in Rare Appendix Cancer Study but Follow-on Research a Challenge
The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...
News Medical1mon
When CDK12/13 stalls, healthy prostate cells take a malignant turn
researchers investigated whether loss of the cyclin-dependent kinase 12 (CDK12) gene drives prostate cancer (PCa) development. Cyclin-dependent kinase enzymes (CDKs) are of two types: cell cycle ...
BioWorld28d
TYK Medicines describes new CDK2/cyclin E1 inhibitors for cancer
A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Business Wire24d
Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
Geoffrey Shapiro, MD, Ph.D., senior vice president, Development Therapeutics at Dana-Farber Cancer Institute and ... excited to see Circle Pharma’s cyclin A/B RxL inhibitor move into the clinic." ...
Joplin Globe16d
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
Notably, tumor regressions were observed in small-cell lung cancer (SCLC), non-small-cell ... CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that ...
Business Wire1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
Current methods targeting cyclin-dependent kinases can be ... of transforming the lives of people living with cancer,” said Clive R. Wood, Ph.D., Senior Vice President and Global Head of ...